The impact of the adoption of the 21-gene recurrence score (RS) assay on receipt of chemotherapy in a study of 44,044 Medicare patients with early-stage breast cancer was strongly population dependent and was associated with relatively lower chemotherapy use with high-risk disease and relatively higher chemotherapy use in patients with low-risk disease. Study details included:
• Assay use was associated with lower chemotherapy use in high risk patients (OR, 0.36) and greater chemotherapy use in low-risk patients (OR, 3.71) compared with no receipt of the assay.
• Use of the RS assay may have decrease chemotherapy use in general practice among younger patients with high-risk disease in whom receipt of chemotherapy would have otherwise been likely.
• Overall, the use of chemotherapy decreased during the study period in patients who were most likely to receive chemotherapy.
Citation: Dinan MA, Mi X, Reed SD, Lyman GH, Curtis LH. Association between use of the 21-gene recurrence score assay and receipt of chemotherapy among Medicare beneficiaries with early-stage breast cancer, 2005-2009. JAMA Oncol. [Published online ahead of print August 27, 2015]. doi: 10.1001/jamaoncol.2015.2722.